The round also attracted participation from the Global Innovation Fund (GIF), Africa Health Ventures, and other investors.

The investment builds on a USD 500,000 commitment from the Global Innovation Fund earlier this year and marks another step in Reme-D’s effort to strengthen local production of advanced molecular diagnostics in Africa.

The company will use the funding to increase manufacturing capacity, broaden its regional footprint, and expand its portfolio into genetic disease and cancer diagnostics.

Founded in 2023 by Salma Tammam, the Cairo-based company develops and manufactures molecular diagnostic tests for diseases including tuberculosis (TB), HIV, hepatitis, and human papillomavirus (HPV).

Unlike many conventional diagnostic products, Reme-D’s tests are engineered to remain stable at higher temperatures, reducing dependence on refrigerated storage and transport.

That makes them easier to distribute to remote communities and healthcare facilities where reliable cold-chain infrastructure is limited.

Since its launch, Reme-D has developed and commercialized 30 diagnostic products and supplied more than 550,000 tests across Egypt, Kenya, and Sudan.

The company serves public and private laboratories, hospitals, and research institutions, while its proprietary technology has also been the subject of a U.S. patent application.

More recently, Reme-D equipped a solar-powered mobile laboratory commissioned by the World Health Organization’s Egypt Office to support the Egyptian Ministry of Health’s monitoring of vector-borne diseases in remote areas.

The new funding will support Reme-D’s move into a 1,500-square-meter manufacturing facility, where upgraded equipment is expected to increase production capacity tenfold.

Alongside expanding manufacturing, the company plans to strengthen its quality and regulatory capabilities while entering new African markets.

“Success means that patients in Africa and the Global South are no longer blocked from life-altering disease diagnosis by cost or availability of an advanced molecular test in their area. This is our ultimate goal,” said Salma Tammam, Founder and CEO of Reme-D.

She added that the company is proud to demonstrate the contribution African science and African women can make to global healthcare innovation while working alongside investors committed to measurable impact.

Mohamed Hussain, Principal at Anara Impact Capital, said the investment firm was attracted by Reme-D’s combination of scientific expertise and practical understanding of healthcare delivery in underserved markets.

He said the company has already demonstrated that high-quality molecular diagnostics can be developed and manufactured locally and is well positioned to expand its impact across the Middle East, Africa, and beyond.